PLoS ONE · 2019 · 24 citations · 33 references
MedicineCancer BiologyOncologyBreast OncologyMetastasisMolecular OncologyCancer BiomarkersCancer ProgressionImmuno-oncology BiomarkersMalignant NeoplasmsMetastatic Breast CancerBreast Cancer ProgressionCancer Metastasis BiomarkersPrognostic Marker AssessmentPrognostic Marker EvaluationPrognostic VariablesTriple-negative Breast Cancer RecurrenceTumor Metastasis BiologyTumor-specific Biomarkers
BACKGROUND: A20 protein has ubiquitin-editing activities and acts as a key regulator of inflammation and immunity. Previously, our group showed that A20 promotes tumor metastasis through multi-monoubiquitylation of SNAIL1 in basal-like breast cancer. Here, we investigated survival outcomes in patients with breast cancer according to A20 expression. PATIENTS AND METHODS: We retrospectively collected tumor samples from patients with breast cancer. Immunohistochemistry (IHC) with an A20-specific antibody was performed, and survival outcomes were analyzed. RESULTS: A20 expression was evaluated in 442 patients. High A20 expression was associated with advanced anatomical stage and young age. High A20 expression showed significantly inferior recurrence-free-survival and overall-survival (P<0.001 and P<0.001, respectively). Multivariate analysis showed that A20 was an independent prognostic marker for RFS (HRs: 2.324, 95% CIs: 1.446-3.736) and OS (HRs: 2.629, 95% CIs: 1.585-4.361). In human epidermal growth factor receptor 2 (HER2)-positive and triple negative breast cancer (TNBC) subtypes, high A20 levels were associated with poor OS. CONCLUSION: We found that A20 expression is a poor prognostic marker in breast cancer. The prognostic impact of A20 was pronounced in aggressive tumors, such as HER2-positive and TNBC subtypes. Our findings suggested that A20 may be a valuable target in patients with aggressive breast cancer.
33
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling
Ingrid E. Wertz, Karen O’Rourke, Honglin Zhou et al. · Nature · 2004 · 1.8K citations
Failure to Regulate TNF-Induced NF-κB and Cell Death Responses in A20-Deficient Mice
Eric G. Lee, David L. Boone, Sophia Chai et al. · Science · 2000 · 1.4K citations · Full text